Insider · CIK 0001944721
Avraham Ben-Tzvi
Files at TTNP (TITAN PHARMACEUTICALS INC), BGMS (Cyclacel Pharmaceuticals, Inc.), FIEE (MINIM, INC.), INDP (Indaptus Therapeutics, Inc.), QUCY (Quantum Cyber N.V.). First filing -, latest -.
In brief
Avraham Ben-Tzvi files SEC Form 4 as director at TTNP (TITAN PHARMACEUTICALS INC), and also at BGMS (Cyclacel Pharmaceuticals, Inc.), FIEE (MINIM, INC.), INDP (Indaptus Therapeutics, Inc.), QUCY (Quantum Cyber N.V.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Avraham Ben-Tzvi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | QUCY Quantum Cyber N.V. | AGrant or award Ordinary Shares | +112,859 | $0.00 | $0 | 252,000 | Aug 6, 2026 |
| Jul 31, 2026 | QUCY Quantum Cyber N.V. | AGrant or award Ordinary Shares | +112,259 | $0.00 | $0 | 251,400 | Aug 5, 2026 |
| May 8, 2026 | QUCY Quantum Cyber N.V. | AGrant or award Ordinary Shares | +137,141 | $0.00 | $0 | 139,141 | May 26, 2026 |
| Jan 20, 2026 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 25,100 | Jan 22, 2026 |
| Dec 23, 2025 | INDP Indaptus Therapeutics, Inc. | AGrant or award Option to Buy Common Stockderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 22, 2026 |
| Oct 1, 2025 | TTNP TITAN PHARMACEUTICALS INC | DDisposition to issuer Common Stock | -3,313 | - | - | 0 | Oct 8, 2025 |
| Oct 1, 2025 | TTNP TITAN PHARMACEUTICALS INC | DDisposition to issuer Option to Purchase Common Stockderivative | -1,250 | - | - | 0 | Oct 8, 2025 |
| Oct 1, 2025 | TTNP TITAN PHARMACEUTICALS INC | DDisposition to issuer Option to Purchase Common Stockderivative | -5,000 | - | - | 0 | Oct 8, 2025 |
| Feb 26, 2025 | BGMS Cyclacel Pharmaceuticals, Inc. | AGrant or award Non-Qualified Stock Option (Right to Buy)derivative | +700,000 | $0.00 | $0 | 700,000 | Feb 28, 2025 |
| Jan 22, 2024 | FIEE MINIM, INC. | AGrant or award Common Stock | +25,000 | - | - | 25,000 | Jan 24, 2024 |
| Oct 25, 2023 | TTNP TITAN PHARMACEUTICALS INC | AGrant or award Common Stock | +16,250 | $0.00 | $0 | 66,250 | Oct 26, 2023 |
Questions about Avraham Ben-Tzvi
Answered from the filings on this page, as of the latest one.
Is Avraham Ben-Tzvi buying or selling?
Avraham Ben-Tzvi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Avraham Ben-Tzvi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Avraham Ben-Tzvi has 0.
Where does Avraham Ben-Tzvi file Form 4?
Avraham Ben-Tzvi has filed Form 4 at TTNP (TITAN PHARMACEUTICALS INC); BGMS (Cyclacel Pharmaceuticals, Inc.); FIEE (MINIM, INC.); INDP (Indaptus Therapeutics, Inc.); QUCY (Quantum Cyber N.V.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.